Literature DB >> 30370955

Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).

Tomas Jelinek1,2,3,4, Jana Mihalyova1,2, Michal Kascak1,2, Juraj Duras1,2, Tereza Popkova1, Katerina Benkova1,2, Petra Richterova1,2, Hana Plonkova1, Jana Zuchnicka1, Lucie Broskevicova1, Lucie Huvarova1,3, Lucie Cerna1, Katerina Growkova1,3, Michal Simicek1,2,3, Martin Havel2,5, Jaromir Gumulec1,2, Milan Navratil1,2, Zdenek Koristek1,2, Bruno Paiva4, Roman Hajek1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30370955     DOI： 10.1002/ajh.25331

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  9 in total

1.  Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report.

Authors:  Yang Yang; Li-Juan Fu; Chun-Mei Chen; Mei-Wei Hu
Journal:  World J Clin Cases       Date:  2021-02-16       Impact factor: 1.337

Review 2.  A clinical perspective on plasma cell leukemia; current status and future directions.

Authors:  Sherilyn A Tuazon; Leona A Holmberg; Omar Nadeem; Paul G Richardson
Journal:  Blood Cancer J       Date:  2021-02-04       Impact factor: 11.037

Review 3.  Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams.

Authors:  Darren Pan; Joshua Richter
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

4.  Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.

Authors:  Virág Réka Szita; Gábor Mikala; András Kozma; János Fábián; Apor Hardi; Hussain Alizadeh; Péter Rajnics; László Rejtő; Tamás Szendrei; László Váróczy; Zsolt Nagy; Árpád Illés; István Vályi-Nagy; Tamás Masszi; Gergely Varga
Journal:  Pathol Oncol Res       Date:  2022-02-28       Impact factor: 3.201

Review 5.  Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.

Authors:  Michael D Diamantidis; Sofia Papadaki; Evdoxia Hatjiharissi
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

6.  Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.

Authors:  Davine Hofste Op Bruinink; Rowan Kuiper; Mark van Duin; Tom Cupedo; Vincent H J van der Velden; Remco Hoogenboezem; Bronno van der Holt; H Berna Beverloo; Erik T Valent; Michael Vermeulen; Francesca Gay; Annemiek Broijl; Hervé Avet-Loiseau; Nikhil C Munshi; Pellegrino Musto; Philippe Moreau; Sonja Zweegman; Niels W C J van de Donk; Pieter Sonneveld
Journal:  J Clin Oncol       Date:  2022-03-31       Impact factor: 50.717

7.  Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.

Authors:  Bharat Nandakumar; Shaji K Kumar; Angela Dispenzieri; Francis K Buadi; David Dingli; Martha Q Lacy; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Amie Fonder; Miriam Hobbs; Yi Lisa Hwa; Eli Muchtar; Rahma Warsame; Taxiarchis V Kourelis; Stephen Russell; John A Lust; Yi Lin; Mustaqeem Siddiqui; Ronald S Go; Dragan Jevremovic; Robert A Kyle; Morie A Gertz; S Vincent Rajkumar; Wilson I Gonsalves
Journal:  Mayo Clin Proc       Date:  2021-03       Impact factor: 7.616

Review 8.  Practical management and assessment of primary plasma cell leukemia in the novel agent era.

Authors:  A Visram; A Suska; A Jurczyszyn; W I Gonsalves
Journal:  Cancer Treat Res Commun       Date:  2021-06-08

9.  Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma.

Authors:  Diana Basali; Rajshekhar Chakraborty; Lisa Rybicki; Nathaniel Rosko; Janice Reed; Maryann Karam; Kristen Schlueter; Hayley Dysert; Matt Kalaycio; Jason Valent
Journal:  Br J Haematol       Date:  2020-02-03       Impact factor: 8.615
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.